Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Common Treatment May Be Removed In Alcoholic Hepatitis Trials

Apr 06 2018

• By Derrick Gingery

Related Content

Rare Diseases: Growing Understanding Will Unlock Accelerated Approval, FDA Says

Oct 19 2017

Deleting The 'Alcohol' From Alcoholic Liver Disease

Apr 06 2018

How Do You Solve A Problem Like Biopsy In Alcohol-Associated Liver Disease?

Apr 06 2018

Target's NASH Study Captures Real World Data, Helps Partners With Trial Design

Jan 15 2018

Pipeline Watch: Phase III Starts With NSR-REP1 Gene Therapy, ALLN-177 And BIVV009

Mar 09 2018

Pipeline Watch: Phase III Progress With Avelumab, Ixekizumab And Eravacycline

Feb 16 2018

Intercept’s NASH Phase III Enrolling Slowly; Gilead Could Gain Ground

Jan 13 2017

Related Companies

Conatus Pharmaceuticals Inc.

Novartis AG

Intercept Pharmaceuticals, Inc.

Gilead Sciences, Inc.

Immuron Ltd.

Additional Topics

United States Drug Approval Standards Clinical Trials FDA Regulation Gastrointestinal BioPharmaceutical

More from Approval Standards

More from Pathways & Standards

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window